The company's Q3 earnings beat estimates but "it remains too early to call for a broad recovery" in the medical-device and consumer businesses.
The company's longest-serving finance chief, who presided over three of its largest acquisitions, will be replaced by investor relations VP Joseph Wolk.
The chief executives of two health-care giants want the industry to move further toward payments based on quality of care.
Tepid growth in pharmaceuticals and consumer products held back first-quarter sales but the company is still confident it will meet its full-year guidance.
The largest acquisition in J&J's history gives it access to Actelion's portfolio of high-margin treatments for rare diseases.
Earnings jumped 19% to $3.81 billion in the fourth quarter, but sales were hit by slowing demand for medical devices.
